Form 4: Belite Bio Insider Sells Shares Under 10b5-1 Plan

Belite Bio's Chief Scientific Officer, Nathan L. Mata, reported the sale of American depositary shares under a pre-arranged trading plan.

Summary

• Nathan L. Mata, Chief Scientific Officer of Belite Bio, Inc., reported transactions involving the sale of American depositary shares (ADS) on May 6, 2026.
• These sales were executed under a Rule 10b5-1 trading plan established on December 10, 2025.
• The total number of ADS sold is not explicitly stated but can be inferred from the changes in beneficial ownership.
• The sales occurred at various weighted average prices ranging from $151.17 to $154.64.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the reported sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which is a standard practice for insiders.

Negatives

• Insider selling can sometimes be perceived negatively by the market, although this sale was conducted under a pre-established trading plan.

Risks

• The filing does not explicitly detail specific risks associated with these transactions beyond the standard implications of insider selling.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future company performance or transactions.

Management Comments

• The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price for weighted average sales.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common and are designed to provide an affirmative defense against allegations of insider trading by allowing executives to sell shares at predetermined times and prices. This filing indicates a routine transaction rather than a signal of negative sentiment about the company's prospects.

Stakeholder Impact

• Shareholders: The sale of shares by an insider, even under a 10b5-1 plan, may lead to questions about the insider's confidence in the company's future performance, though the plan's existence mitigates concerns about opportunistic trading.

Next Steps

• The reporting person has undertaken to provide further details on specific sale prices upon request.

Key Dates

Keywords

Belite Bio, BLTE, Form 4, Insider Trading, Rule 10b5-1, ADS Sale, Nathan L. Mata, Securities Transaction